Inotek Pharmaceuticals Corporation

100 Cummings Center
Beverly, MA 01915
http://www.inotekcorp.com

Market Performance

NASDAQ: ITEK
Market Cap $68.1 Million
52 Week High $7.95
52 Week Low $0.85

SBIR Award Summary

Total Number of Awards 103
Total Value of Awards $31.8MM
First Award Date 05/01/97
Most Recent Award Date 07/01/07

Key Personnel

Last Name Name Awards Contact
Southan Garry John Southan 30
Hasko Gyorgy Hasko 5
Murthy Kanneganti Murthy 3
Mabley Jon G Mabley 8
Virag Laszlo Virag 3
Szabo Csaba Szabo 15
Salzman Andrew L Salzman 19
Jagtap Prakash Jagtap 5
Nivorozhkin Alex Nivorozhkin 1
Pacher Pal Pacher 1
Zsengeller Zsuzsanna Kinga Zsengeller 2
Zuo Fangming Zuo 2
Marton Anita Marton 4
Belayev Ludmila Belayev 2
Stachlewitz Robert F Stachlewitz 1
Gaeldin Abdelkarim Gaeldin 1
Van Duzer John H Van Duzer 1

103 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/07 - 06/30/08

DESCRIPTION (provided by applicant): Steroid treatment of anterior uveitus is effective but frequently associated with cataract formation after prolonged use. Development of an effective substitute for steroids, free of these safety concerns, would be a substantial advance. In a Phase I SBIR, we proposed a novel therapeutic candidate for treatme...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/05 - 06/30/07

DESCRIPTION (provided by applicant): Steroid treatment of anterior uveitus is effective but frequently associated with cataract formation after prolonged use. Development of an effective substitute for steroids, free of these safety concerns, would be a substantial advance. In a Phase I SBIR, we proposed a novel therapeutic candidate for treatme...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/05 - 11/30/07

DESCRIPTION (provided by applicant): This Phase II SBIR proposal is intended to further develop a new therapeutic approach to save the lives of severely injured trauma victims with hemorrhagic shock (HS). In a small proportion of trauma, a fatal outcome is assured due to the irreversible loss of vital functions or massive blood loss. Frequent...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/05 - 09/30/06

DESCRIPTION (provided by applicant): Ischemia-reperfusion (I/R) produces tissue injury and systemic inflammatory response syndrome (SIRS). The mechanism by which oxidants effect these changes has recently been ascribed to their impact on genomic integrity. Oxidants rapidly induce DNA single strand breaks that activate the nuclear enzyme poly ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/04 - 03/29/05

DESCRIPTION (provided by applicant): The current Phase I SBIR Grant application by Inotek Pharmaceuticals Corporation proposes to test the antinociceptive effect of a novel A1 receptor agonist in rat models. As preliminary data we present evidence in cultured cells expressing various human Al receptor subtypes that the compound PJ8-75 is ultrapo...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/04 - 11/30/06

DESCRIPTION (provided by applicant): Stroke activates the nuclear enzyme poly (ADP-ribose) polymerase ("PARP"), triggering cells to undergo necrosis and inflammation. Inotek's ultrapotent clinical PARP inhibitor ("INO-1001') profoundly reduces tissue necrosis and neurologic dysfunction in transient and permanent ischemic rat stroke models. Our d...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/04 - 09/14/06

DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is mediated by articular expression of pro-inflammatory cytokines and chemokines. We have discovered that the purine degradation product inosine exerts multiple anti-inflammatory and immunomodulatory effects via combined A2a and A3 agonism, resulting in suppressed expression of TNF-...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/04 - 03/14/06

DESCRIPTION (provided by applicant): Progression of septic shock to multiple organ failure (MOF) is mediated by the activation of poly(ADP-ribose) polymerase ("PARP"), a nuclear cell death enzyme that catalyzes intracellular energetic failure and necrosis. Genetic deletion or pharmacologic inhibition of PARP is profoundly protective in models...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/04 - 02/28/06

DESCRIPTION (provided by applicant): The current application represents a Phase I SBIR Grant application by Inotek Corporation, proposing to establish a proof-of-concept of the involvement of poly (ADP-ribose) polymerase (PARP) activation in the pathogenesis of diabetic erectile dysfunction. As preliminary data we present evidence in cultured ce...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/04 - 08/31/05

DESCRIPTION (provided by applicant): Xanthine oxidase (XO)-catalyzed generation of superoxide anion is thought to contribute to the pathogenesis of autoimmune arthritis. The relative importance of XO to the pathogenesis of arthritis is demonstrated in numerous rodent models of autoimmune arthritis in which allopurinol, a prototypic XO inhibit...

Load More